{"keywords": [{"value": "Turing Pharmaceuticals AG", "rank": "1", "is_major": "Y", "name": "organizations"}, {"value": "Drugs (Pharmaceuticals)", "rank": "2", "is_major": "Y", "name": "subject"}, {"value": "New York State", "rank": "3", "is_major": "Y", "name": "glocations"}, {"value": "Schneiderman, Eric T", "rank": "4", "is_major": "Y", "name": "persons"}, {"value": "Shkreli, Martin (1983- )", "rank": "5", "is_major": "Y", "name": "persons"}, {"value": "Prices (Fares, Fees and Rates)", "rank": "6", "is_major": "N", "name": "subject"}], "headline": {"print_headline": "New York Attorney General Examining if Turing Restricted Drug Access", "main": "New York Attorney General Examining Whether Turing Restricted Drug Access"}, "byline": {"contributor": "", "original": "By ANDREW POLLACK", "person": [{"rank": 1, "role": "reported", "organization": "", "lastname": "POLLACK", "firstname": "Andrew"}]}, "web_url": "http://www.nytimes.com/2015/10/13/business/new-york-attorney-general-examining-if-turing-restricted-drug-access.html", "source": "The New York Times", "subsection_name": null, "slideshow_credits": null, "type_of_material": "News", "_id": "561c538238f0d84d2f3b8ac8", "multimedia": [{"height": 126, "subtype": "wide", "legacy": {"widewidth": "190", "wideheight": "126", "wide": "images/2015/10/13/business/13drug-web1/13drug-web1-thumbWide.jpg"}, "type": "image", "width": 190, "url": "images/2015/10/13/business/13drug-web1/13drug-web1-thumbWide.jpg"}, {"height": 400, "subtype": "xlarge", "legacy": {"xlargeheight": "400", "xlargewidth": "600", "xlarge": "images/2015/10/13/business/13drug-web1/13drug-web1-articleLarge.jpg"}, "type": "image", "width": 600, "url": "images/2015/10/13/business/13drug-web1/13drug-web1-articleLarge.jpg"}, {"height": 75, "subtype": "thumbnail", "legacy": {"thumbnailwidth": "75", "thumbnailheight": "75", "thumbnail": "images/2015/10/13/business/13drug-web1/13drug-web1-thumbStandard-v4.jpg"}, "type": "image", "width": 75, "url": "images/2015/10/13/business/13drug-web1/13drug-web1-thumbStandard-v4.jpg"}], "pub_date": "2015-10-13T00:00:00Z", "print_page": "4", "section_name": "Business Day", "word_count": "785", "blog": [], "news_desk": "Business", "snippet": "Eric T. Schneiderman has begun an inquiry into whether Turing Pharmaceuticals violated antitrust rules by restricting distribution of a drug, Daraprim, as a way to thwart generic competition.", "document_type": "article", "abstract": "New York State Atty Gen Eric T Schneiderman starts investigation into Turing Pharmaceuticals, which skyrocketed price of infection drug, causing backlash against high pharmaceutical prices; Schneiderman's office has addressed letter of inquiry directly to Turing head Martin Shkreli. ", "lead_paragraph": "Eric T. Schneiderman has begun an inquiry into whether Turing Pharmaceuticals violated antitrust rules by restricting distribution of a drug, Daraprim, as a way to thwart generic competition."}